Welcome to OncBioMune Pharmaceuticals Inc.

We are a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a proprietary vaccine technology that is designed to stimulate the immune system to selectively attack cancer cells without harm to the patient.  The vaccine technology has been proven safe through use in more than 300 patients without a single serious adverse event.  Our lead product, ProscaVax™ for prostate cancer, is near conclusion of a Phase 1 trial funded by the Department of Defense Navy Cancer Vaccine Program.  Based upon data showing ProscaVax is non-toxic and can lower PSA levels, we are moving ProscaVax into a Phase 2 trial for prostate cancer patients in the “Active Surveillance” category, an early stage of disease for which there are currently no treatments without significant morbidities. OncBioMune also has a portfolio of targeted therapies, some of which are biosimilars to blockbuster drugs, including paclitaxel (Abraxane).



Subscribe to our email list
* indicates required

Latest News: Site Visit Planned for December 19, 2018 to Initiate Phase 2 Trial of ProscaVax for Early-Stage Prostate Cancer

OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) is pleased to provide an update on the Phase 2 clinical trial of ProscaVax being hosted at Beth Israel Deaconess Medical Center (BIDMC), a teaching hospital of Harvard University.  In the clinical trial, ProscaVax, the Company’s lead immunotherapeutic cancer vaccine consisting…. (continue reading)

Latest News: OncBioMune Phase 2 Clinical Trial to Begin Enrollment; Company Announces Other Development and Corporate Milestones

OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) today announces the signing of a work order with leading Contract Research Organization, Theradex Oncology (“Theradex”), detailing the scope to be provided by Theradex for a clinical trial titled, “A Phase 2 Study of a PSA/IL-2/GM-CSF Vaccine for the Treatment of PSA-Recurrent Prostate Cancer in Hormone-Naïve Patients.” … (continue reading)

Here’s what prostate cancer patients have to say about ProscaVax:

“I am very thankful for the 14 years of active life that was provided by my choice to take the vaccine under Dr. Head’s supervision. It is a treatment that insured by quality of life, and encouraged me to enthusiastically participate in the healing process. It is a treatment I believe in and I heartily recommend it to any prostate cancer victim who qualifies for it.”
Edward Pramuk - LSU Professor Emeritus, Read the full testimonial
“I am confident that the vaccine Dr. Elliott has been working on for nearly two decades is the reason that I am still alive and well and able to live a fulfilling life. Since receiving it, I have urged other men to consider this treatment which was successful for me.”
“I wanted to take this opportunity to express my profound gratitude to you, Dr. Jonathan Head, and the other members of your medical team for the key role you’ve played in keeping me alive and perfectly healthy over this time [10 years]. I can confidently state that the attention you’ve devoted to my case as well as the ongoing evaluation and periodic administration of your prostate cancer vaccine have controlled my cancer problem very effectively.”
Steven Karalekas, Read the full testimonial

PROSTATE CANCER

The Company has developed a therapeutic cancer vaccine, called ProscaVax™, for  prostate cancer patients using similar techniques developed for breast cancer patients. ProscaVax™ is tested, laboratory proven and currently in clinical trials.  OncBioMune is optimistic that it could one day become a standard of care for prostate cancer treatment.

LEARN MORE

BREAST CANCER

Breast cancers and other epithelial malignancies are antigenic and elicit lymphocyte responses in the autologous host, and patients that express good host immunity to their tumor have better survival. Adequate host immunity is an independent prognostic indicator and those with poor immunity have  shorter disease free intervals and shorter overall survival.

LEARN MORE

INNOVATIVE CHEMOTHERAPY

Targeted Transferrin Transport Technology” – OncBioMune has developed a strategy to increase the efficacy and lessen the toxicity of cancer chemotherapy by binding heavy metals and coupling chemotherapeutic drugs to the serum protein transferrin.

LEARN MORE

ANTISENSE

Antisense oligonucleotide are defined as the oligodeoxyribonucleotide (oDNA) sequence that is complementary to the DNA or RNA sequence of the target gene. Antisense RNA defined as the antisense cDNA, which is complementary to the RNA sequence of the gene.

LEARN MORE

164,690 MEN WILL BE DIAGNOSED WITH
PROSTATE CANCER THIS YEAR

29,430 MEN WILL DIE FROM THE DISEASE

A VACCINE CAN
CHANGE THAT

LEARN MORE